编辑推荐：针对BRAF-V600E突变型转移性结直肠癌（mCRC），FDA已批准Encorafenib联合Cetuximab和mFOLFOX6一线治疗方案；同时CheckMate 8HW ...

来自某癌症中心的研究团队针对BRAF V600E突变型转移性结直肠癌（mCRC）患者，探究了早期肿瘤退缩（ETS）和缓解深度（DpR）对 ...

The BRAF mutation in lung cancer means that your cancer started due to a change in the BRAF gene. It may affect your treatment options and outlook. The BRAF gene is partially responsible for cell ...

Researchers at the University of California San Diego have uncovered a key mechanism underlying the treatment resistance of melanoma with the BRAF V600E mutation through pathways involved in focal ...

Vemurafenib (ZELBORAF, Hoffmann-La Roche Inc; Figure 1) is a first-in-class selective inhibitor of the BRAF serine-threonine kinase, FDA approved for the treatment of metastatic melanoma harboring ...

Novartis' two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for solid tumours that have a BRAF V600E mutation – regardless of where they occur in the body.

Personalized Medicine. 2013;10(4):405-412. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict ...

The focus is on the potential impact of BRAFTOVI for patients with mCRC with a BRAF V600E mutation, reflecting Pfizer's dedication to providing innovative cancer treatments.

Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer last month, and it already has survival data that could see that ...

Dabrafenib 10mg; tabs for oral susp; berry-flavored. In combination with trametinib for the treatment of pediatric patients with low-grade glioma (LGG) with a BRAF V600E mutation who require ...